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Abstract
The role of molecular changes in the androgen receptor (AR) as AR variants (AR-Vs) is not
clear in the pathophysiology of benign prostatic hyperplasia (BPH) and hormone-naïve
PCa. The aim of the current work was to identify the presence of AR isoforms in benign tis-
sue and primary PCa, and to evaluate the possible association with tumor aggressiveness
and biochemical recurrence in primary PCa. The mRNA levels of full length AR (AR-FL) and
AR-Vs (AR-V1, AR-V4 and AR-V7) were measured using RT-qPCR. The protein expression
of AR-FL (AR-CTD and AR-NTD) and AR-V7 were evaluated by the H-Score in immunohis-
tochemistry (IHC). All investigated mRNA targets were expressed both in BPH and PCa.
AR-FL mRNA levels were similar in both groups. AR-V4 mRNA expression showed higher
levels in BPH, and AR-V1 and AR-V7 mRNA expression were higher in PCa. The AR-V7
protein showed a similar H-Score in both groups, while AR-CTD and AR-NTD were higher in
nuclei of epithelial cells from BPH. These results support the assumption that these constitu-
tively active isoforms of AR are involved in the pathophysiology of primary PCa and BPH.
The role of AR-Vs and their possible modulation by steroid tissue levels in distinct types of
prostate tumors needs to be elucidated to help guide the best clinical management of these
diseases.
Introduction
Prostate cancer (PCa) is the most common neoplasia among Brazilian men, with 68,220 new
cases estimated for the year 2018, corresponding to an estimated risk of 66.12 new cases per
100 thousand men, only behind non-melanoma skin cancer [1]. As prostatic cell growth is
androgen dependent, androgen ablation therapy has become the mainstay of treatment for
patients with PCa [2]. However, following a period of initial response, prostate cancer cells can
acquire the ability to proliferate despite very low circulating concentrations of androgen. This
androgen-independent proliferation is clinically significant, because the majority of men who
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develop resistance to hormonal therapy do not respond to currently available therapies. Dur-
ing this therapy resistance phase, the activation of androgen receptors (AR) may occur inde-
pendently of hormone binding [3, 4]. It is speculated that prostate cells use different
mechanisms to compensate for androgenic deprivation, and, recently, androgen receptor
splice variants (AR-Vs) have been associated with that androgen-independent growth [5].
The AR gene is composed of eight exons encoding a 110 kD protein. The AR protein com-
prises different domains: an N-terminal domain (NTD), encoded by exon 1; a DNA-binding
domain (DBD), encoded by exons 2 and 3; and the ligand-binding domain (LBD), encoded by
exons 4 to 8, which is the region where hormone binding occurs [5, 6]. When the hormone
binds to LBD, it allows the translocation of the receptor to the nucleus and the subsequent
transcriptional regulation of androgen-responsive genes [7]. However, although AR-Vs lose
LBD, they allow the AR signal to occur, even in the absence of androgen [5, 8–12]. Among the
variants already identified, AR-V7 is the most thoroughly studied to date [5, 9, 10]. However,
the role of AR-Vs in the pathophysiology of benign prostatic hyperplasia (BPH) and hormone-
responsive PCa needs to be better clarified [5]. Some authors have reported the presence of iso-
forms in normal tissue [9–11, 13]; however, those samples were obtained from normal tissue
of a prostate with cancer. It is noteworthy that samples of tissue adjacent to tumors, although
morphologically confirmed as non-neoplastic tissue, can present molecular alterations like
those found in malignant tissue (unpublished data). Some authors, when analyzing isoform
gene expression, observed that AR-Vs are expressed at levels substantially lower than AR-FL
[5, 9, 12]. In castration-resistant PCa (CRPC) samples, the AR-V expression levels are signifi-
cantly higher than the samples of primary PCa, and their expression is associated with a worse
clinical outcome [5, 9]. In addition, they have been associated with increased disease recur-
rence after radical prostatectomy compared with patients with low expression of AR-Vs [9].
The AR-Vs can have an important role in the complex regulatory mechanism of tumor cell
proliferation and drive molecular changes in this tissue. AR-Vs present an interesting complex
interaction between themselves. Heterodimerization between AR-Vs and with AR-FL could
have important impact at cellular level [14]. As demonstrated by Zhan et al. [14], AR-V7 het-
erodimerizes with AR-V1, AR-V4 and AR-V6, which facilitates its nuclear localization. These
isoforms could also dimerize with AR-FL, even in the absence of androgen. When dimerized
to androgen-bound AR-FL, these isoforms are piggybacked into the nucleus. AR-V1 could
heterodimerize with AR-V7 and as consequence the ability of AR-V7 to confer castration-
resistant cell growth is inhibited, which suggest that AR-V1 could act as a negative regulator of
AR-V7. Although this AR-Vs interplay were studied to investigate castration-resistant cell
growth, the presence, interaction and possible consequences of AR-Vs expression should be
taken in consideration even in benign tissue. The molecular mechanisms of AR-Vs interac-
tions still unclear, especially involving cell cycle and apoptosis-related genes. To provide a bet-
ter understanding of the molecular mechanisms of AR-Vs and pathophysiology of prostatic
tumors, in the present work, we investigate the expression of AR-Vs, cell cycle and apoptosis-
related genes in prostate tissue from patients with primary PCa or BPH, and their possible
association with tumor aggressiveness and biochemical recurrence in primary PCa.
Material and methods
Patient selection
Tissue samples from patients with primary PCa (n = 61) or BPH (n = 128) were obtained from
radical prostatectomy, prostatectomy or transurethral ressection (TURP). For mRNA analysis,
25 samples of primary PCa and 30 of BPH were used. For the immunohistochemical analysis,
6 samples of each group were used. The pathological diagnosis of the tissues was confirmed by
AR-Vs in BPH and primary PCa
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the Pathology Service. This study was approved by the Research Ethics Committee of the Hos-
pital de Clı´nicas de Porto Alegre (HCPA). Informed consent was obtained from all individual
participants included in the study. Clinical data for each patient were collected from the hospi-
tal electronic records and any of the authors had access to any information which could poten-
tially identify any individual patients.
Gene expression analysis
Molecular analysis was performed by quantitative PCR (qPCR) following reverse transcription
(RT), with a TaqMan1 probe detection system (Life Technologies™) using 10-fold diluted
samples. The gene for beta-2-microglobulin (B2M) was used as a reference gene for the
stabilization of gene expression levels among the different samples. For amplification of B2M
and AR, inventoried assays from Life Technologies™ were used (Hs00171172_m1 and
Hs00984230_m1, respectively). It is noteworthy that the assay used for AR amplified tran-
scripts 1 and 2 of the receptor (AR-FL). For the design of primers and probes specific for iso-
forms, the mRNA sequences described by Guo et al. [5], and available in UniGene under the
identifications FJ235917.1 (AR-V1), FJ235919.1 (AR-V4), and FJ235916.1 (AR-V7) [5] were
used. We also analyzed the cell cycle-related genes TP53, MDM2, CDKNA and apoptosis-
related genes BAX and BCL2 to study their possible association with AR-Vs and to help
towards a better understanding of the molecular mechanisms of AR-Vs. The sequences of
primers and probes are shown in Table 1.
We designed a specific assay to amplify AR-V1, since a unique region was identified in this
variant, which allowed isolated amplification of this isoform. Due to the close similarity
between the cDNA sequences of isoforms AR-V4 and AR-V7, after careful analysis, the design
of specific assays for these isoforms was not possible; thus, we chose the concomitant amplifi-
cation of the isoforms. Therefore, we designed assays for the joint amplification of transcripts
AR-V4 and AR-V7, and named this transcript AR-V4V7. The same was true for AR-V4 and
AR-V3. Even though both transcripts were amplified together, to simplify understanding, we
refer here the transcript AR-V3V4 as AR-V4. The ratio for AR-V4V7/AR-V4 was calculated to
represent AR-V7 expression, termed here as AR-V7rv (representative value).
Table 1. Sequences of primers and probes used for qRT-PCR.
Target Sequence
B2M Hs00984230_m1
AR-FL Hs00171172_m1
AR-V1 sense 5’—AGGGTGTTTGGAGTCTCAGA—3’
antisense 5’—CCAGGAATGAATCATCTACAAA—3’
probe 5’ -TTCCTTAAAGACTACCTTCAGACTC—3’
AR-V4 sense 5’—GACACTAACCCCAAGCCATAC—3’
antisense 5’ -ACTGTCTGATGTTGCTCTGTG—3’
probe 5’—TTGTTTTCTGTCAGTCCCATTGGTGC—3’
AR-V4V7 sense 5’—CTCTTGATTGCTGACTCCCTC—3’
antisense 5’ -ACAACTACATGAGTGGTAACCA—3’
probe 5’—AGGTAGGAAAACACTATTGGTCCCGC—3’
BAX Hs00180269_m1
BCL2 Hs00608023_m1
CDKN1A Hs00355782_m1
TP53 Hs01034249_m1
MDM2 Hs00242813_m1
https://doi.org/10.1371/journal.pone.0200613.t001
AR-Vs in BPH and primary PCa
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Immunohistochemistry (IHC) of AR-Vs
We chose to use three different antibodies to investigate AR expression. The PG21 antibody
recognizes the N-terminal domain (NTD), which is encoded by AR-FL and AR-Vs. Because of
this, antibodies recognizing AR-NTD detect both AR-FL and AR-Vs. The C-19 antibody rec-
ognizes the C-terminal domain (CTD), and since LBD-truncated AR-Vs lacks the CTD region,
they are consequently not recognized by the C-19 antibody. An alternative approach to detect
the presence of AR-Vs is to combine data obtained using antibodies recognizing AR-NTD and
AR-CTD, respectively.
IHC was performed on 4-μm sections derived from FFPE blocks using the mouse AR-V7
monoclonal antibody (Precision Antibody), diluted 1:200; the rabbit polyclonal AR (C-19)
(Santa Cruz), diluted 1:400; and the rabbit polyclonal AR (PG21) (Millipore), diluted 1:400.
Antigen retrieval was achieved by heating in a water bath the slides in citrate buffer (pH 6.0)
for 1 hour at 95˚C. Endogenous peroxidase was blocked using 3% H2O2 solution in methanol
for 30 minutes. The reaction was visualized using DAB chromogen (Liquid Dab, Dako) fol-
lowed by counterstaining with Harris hematoxylin. Cases were scored blind by two evaluators
as clinical data using the modified H-score (histological score) method, a semiquantitative
assessment of staining intensity that reflects antigen concentration [15, 16]. Briefly, the H-
score was determined according to the formula: [(% of weak staining) x 1] + [(% of moderate
staining) x 2] + [(% of strong staining) x 3], yielding a range from 0 to 300 [15, 16].
Statistical analysis
Data are reported as mean (standard deviation) when parametric, and as median values with
interquartile range (IQR) when non-parametric, and analyzed by Student’s t-test or Mann-
Whitney U test, respectively. In order to verify the association between the results of isoform
gene expression and the other continuous variables, a Spearman’s rank correlation was per-
formed. All P values were two-sided and P<0.05 was considered significant. All statistical anal-
yses were performed using SPSS 20.0 program. Graphs were constructed using SPSS or
GraphPad.
Results
Sample characterization
Clinical characteristics of patients are described in Table 2. Among the 61 PCa samples, 40
(66.7%) showed a Gleason score7(3+4), and 20 (33.3%) showed a Gleason score7(4+3).
Table 2. Sample characterization.
BPH PCa P value
Age at surgery, years
Mean (SD)
n = 128
66.70 (8.29)
n = 61
65.85 (8.23)
0.510a
PSA preoperative, ng/ml
Median (IQR)
n = 123
5.00 (6.54)
n = 61
7.41 (6.76)
<0.001b
Estimated prostate weight c, grams
Median (IQR)
n = 89
62.00 (56)
n = 42
36.50 (25)
<0.001b
Surgical specimen weight, grams
Median (IQR)
n = 57
56.00 (35)
n = 55
42.00 (22)
0.001b
a P value was determined T test. P values are corrected for ties
b P value was determined by the Mann–Whitney U test. P values are corrected for ties.
c Prostate weight estimated by ultrasound or digital rectal examination.
https://doi.org/10.1371/journal.pone.0200613.t002
AR-Vs in BPH and primary PCa
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One PCa case had Gleason data missing. Regarding the pathologic staging (pTNM), 4 (7.3%)
were classified as T1, 44 (80.0%) were classified as T2, and 7 (12.7%) as T3. Six PCa cases had
pTNM data missing. After surgery, 18 patients (32.7%) presented biochemical recurrence after
a median of 53 months.
AR-Vs are differentially expressed between BPH and PCa
We detected all analyzed AR transcripts in BPH and primary PCa samples. The mRNA expres-
sion of AR-FL showed no difference between the groups (P = 0.331) (Fig 1A). PCa samples
showed higher AR-V1 gene expression compared to the BPH group (P = 0.041) (Fig 1B). Con-
versely, BPH showed higher AR-V4 gene expression compared to the PCa group (P = 0.001)
(Fig 1C). Using the ratio of AR-V4V7/AR-V4, it was possible determine an indirect value of
AR-V7, termed AR-V7rv. This was more highly expressed in PCa when compared to BPH
(P<0.001) (Fig 1D). When PCa samples were dichotomized based on biochemical recurrence,
a similar expression was observed for all mRNAs analyzed among patients who had biochemi-
cal recurrence and in those who did not present recurrence.
The cell cycle-related and apoptosis-related genes are more expressed in
PCa group
Regarding the expression of BAX, BCL2, TP53, CDKN1A and MDM2, all of these were more
highly expressed in the PCa group (P0.001, P = 0.029, P = 0.011, P = 0.001, P = 0.001, and
P = 0.025) than in the BPH group (Table 3).
AR-NTD and AR-CTD are expressed in higher levels in the nuclei of
epithelial cells from BPH samples
We also analyzed the protein expression of AR-NTD, AR-CTD and AR-V7 by immunohis-
tochemistry. For this analysis, the H-score (HS) was quantified separately in the nucleus and
cytoplasm of epithelial and stromal compartments (Table 4, Fig 2A and 2B). AR-NTD and
AR-CTD had a higher HS in epithelial nuclei of BPH group than in the PCa group (P = 0.034
and P = 0.041, respectively; Fig 2A). AR-V7 seemed to be also more highly expressed in nuclei
of epithelial cells in benign tissue, but failed to reach statistical significance (P = 0.093, Fig 2A).
Indeed, AR-V7 was not differentially expressed in any compartment, but this variant was pres-
ent in epithelial cells from BPH and PCa. AR-V7 was also expressed in the cytoplasm of stro-
mal cells at the same intensity between the groups. On the other hand, stromal nuclei were
positive for AR-NTD, although stromal cytoplasm was positive for AR-V7. Fig 3 shows repre-
sentative images of immunohistochemical staining on epithelial cells. When the H-score
yielded a value lower than 10, results were considered negative and were represented as not
detectable (ND). Using the AR-NTD/AR-CTD ratio, we observed a wide distribution in epi-
thelial nuclei of PCa samples, although it failed to reach statistical significance (P = 0.818)
(Figure in S1 Fig).
We observed positive staining for the three antibodies in all epithelial samples, which is
remarkable since benign tumors (like BPH) and primary cancer are not expected to express
AR-Vs, which are supposed to arise only after androgen deprivation therapy. Nuclear stromal
staining was positive only for AR-NTD in both groups. Although AR-CTD was detectable in
the BPH group, the score was so minimal that it was considered negative. AR-CTD in PCa
samples and AR-V7 in both nuclear stromal groups were negative.
Using Spearman’s rank correlation analysis, we found a positive correlation among AR-Vs
(Table 5). In the PCa group, AR-FL was positively correlated with BCL2 (0.464, P = 0.030;
AR-Vs in BPH and primary PCa
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Fig 1. AR-Vs mRNA expression in BPH and PCa samples. All mRNA data are normalized by beta-2-microglobulin (B2M). For AR-FL, AR-V1 and
AR-V4, values of normalized quantity means (NQM) were used to create the graphs. AR-V7rv was obtained from the ratio between AR-V4V7 and AR-V4.
The bars represent the minimum to maximum values. (A) The median AR-FL expression is not significantly different comparing BPH and PCa (P = 0.331).
(B) and (D) AR-V1 and AR-V7rv expression are higher in primary PCa than in BPH (P = 0.041 and P<0.001, respectively). (C) AR-V4 expression is
AR-Vs in BPH and primary PCa
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Table 6). In the BPH group, AR-V1 and AR-V4 were positively correlated with prostate weight
(0.477, P = 0.025; and 0.711, P<0.001; Table 5). The positive correlation between AR-V4 and
prostate weight is not surprising given that BPH (which presented a higher prostate weight)
has a higher mRNA level of this isoform when compared with PCa. Although AR-V1 was
more highly expressed in PCa, this isoform showed a positive correlation with prostate weight
in the BPH group. In addition, the ratio of BCL2/BAX showed a regular negative correlation
(-0.413, P = 0.036; Table 6) with the surgical specimen weight. In PCa, we found a regular posi-
tive correlation between AR-V4 and Gleason score (0.493, P = 0.0012), suggesting that with
the increase of tumoral aggressivity, there was an increase of AR-V4 expression.
Age at surgery was negatively correlated with the ratios AR-FL/AR-V1 (-0.364, P = 0.048),
AR-FL/AR-V4 (-0.405, P = 0.027) and AR-FL/AR-V4V7 (-0.377, P = 0.040) in the BPH group.
These associations between ratios and age were not found in the PCa group, but in this group,
the ratios AR-FL/AR-V4 and AR-V7rv were positively correlated with BAX (0.472, P = 0.017;
and 0.450, P = 0.024).
Besides the correlation between cell cycle-related and apoptosis-related genes and AR-Vs
and clinical features, these genes were correlated among themselves. The correlations of cell
cycle-related genes (TP53, MDM2, CDKN1A) and apoptosis-related genes (BAX, BCL2 and
ratio BCL2/BAX) are presented in Table 6.
High grade versus low grade PCa
When primary PCa samples were stratified for Gleason score (7(3+4) and7(4+3), high-
grade patients were older (P = 0.047, Fig 4A) and had higher AR-V4 levels (P = 0.004, Fig 4D)
and higher AR-V7rv (P = 0.014, Fig 4E) when compared with the low-grade group. Although
AR-V1 levels did not show statistical significance (P = 0.060, Fig 4C), this variant had a wide
distribution in the high-grade group (7(4+3), which is in concordance with our results from
other isoforms. AR-FL levels (P = 0.836, Fig 4B) were similar between low and high grades.
The ratio of AR-FL/AR-V4 was higher in the low-grade samples (P = 0.021, Fig 4F). Regarding
the biochemical relapse, the mean time until relapse was 53 months. In high-grade PCa, this
time was significantly lower (31 months) than low-grade PCa (65 months) (P = 0.004), repre-
sented by the Kaplan-Meyer curve (Figure in S2 Fig).
In a Cox regression univariable model (Table in S1 Table), the ratio of AR-V1/AR-FL was
associated with a higher risk of biochemical recurrence (HR = 1.172, P = 0.045) and BLC2/
significantly different comparing BPH and PCa (P = 0.001), showing higher levels in hyperplastic tissue. P value was determined by the Mann–Whitney U
test.
https://doi.org/10.1371/journal.pone.0200613.g001
Table 3. Cell cycle-related and apoptosis-related genes mRNA expression.
mRNA
median (interquartile range)
BPH
n = 27
PCa
n = 26
P value
BAX 0.8660 (0.60) 2.1764 (2.64) 0.000
BCL2 0.8114 (0.58) 1.2557 (2.21) 0.029
MDM2 1.0992 (1.66) 3.5086 (6.50) 0.001
TP53 0.9556 (1.12) 1.5580 (2.01) 0.011
CDK1NA 0.6452 (0.62) 2.3317 (3.12) 0.001
P value was determined by the Mann–Whitney U test. P values are corrected for ties.
 P< 0.05 were considered statistically significant.
https://doi.org/10.1371/journal.pone.0200613.t003
AR-Vs in BPH and primary PCa
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BAX was associated with protection of biochemical recurrence (HR = 0.123, P = 0.009). These
associations remained when these variables were tested together in a multivariable model,
(HR = 1.219, P = 0.038; and HR = 0.104, P = 0.014; respectively).
Discussion
We investigated the AR-FL expression using an assay specific for transcripts 1 and 2
(GI:349501065 and GI:349510166), which prevents untrue conclusions about differences in
AR-FL and AR-V expression. We also analyzed AR-V mRNA, and importantly, we detected
the expression of all isoforms in samples from hyperplastic tissue and primary PCa. Truncated
AR-Vs were previously assumed to be expressed primarily in CRPC, where, at least for AR-V7,
their presence was associated with resistance to therapy [17, 18]. This is a remarkable finding
of this work, since we evaluated tissue from hormone-naïve PCa, while others have mostly
evaluated advanced cancer, castration-resistant cancer, metastasis sites or even cell lines [5, 8,
9, 11, 12, 17–23]. Our detection of AR-Vs in BPH complements the data reported in the litera-
ture, which demonstrate the expression of these isoforms in benign tissue from radical prosta-
tectomy for cancer removal, malignant tissue and metastatic sites [5, 8, 9, 11, 12, 18, 22]. This
wide distribution was recently confirmed by a whole transcriptome analysis by The Cancer
Genome Atlas (TCGA), which demonstrated that AR-V7 is the most abundant AR-V
expressed in human cell lines, human xenografts and clinical samples [21]. Our finding that
AR-Vs are expressed in hormone-naïve primary PCa is notable, and is in concordance with
the TCGA study [21]. The data of gene expression showed a large range of variation in both
groups, which was also observed in previous studies [19]. We also found a correlation among
the AR-Vs, which was expected since all isoforms are derived from the same pre-mRNA. The
formation of one or other isoform occurs by mechanisms not precisely described until now,
but it is expected that the resulting molecules are correlated at least to some level.
Together, our findings suggest that these constitutively active isoforms participate in differ-
ent proliferative events in different types of prostatic tumors, not only as the main driver of
castration resistance. During tumor progression, selection for cells that express AR-Vs could
occur, via selection of more malignant or castration-resistant subclones or even via the hor-
mone-dependant regulation of AR isoforms [12]. It has been already demonstrated that AR
isoforms show weak expression in androgen-dependent cell lines (LNCaP and LAPC4), while
in androgen-independent lines, such as CWR22Rv1 and those derived from LNCaP (C81, C4-
2 and C4-2B), the expression of the AR isoforms is significantly higher [5]. These data imply
an inverse correlation between AR isoform expression and the dependence of androgens [5].
It has been demonstrated in vitro by Watson et al. [12] that AR-FL and AR-V (AR-V1 and
Table 4. Histological scores (H-Score) representing the histological staining patterns of AR-NTD, AR-CTD and AR-V7 protein in BPH and PCa samples.
AR-NTD AR-CTD AR-V7
BPH PCa P BPH PCa P BPH PCa P
Nuclei Epithelial 261.8 (23.8) 125.8 (116.2) 0.034a 155.0 (125) 22.5 (91) 0.041b 121.5 (170) 30.0 (65) 0.093 b
Stromal 145.0 (40) 19.5 (121) 0.065b ND ND ND ND ND ND
Cyto-plasm Epithelial 156.7 (55.6) 215.0 (65.6) 0.128a 222.5 (159) 280.0 (86) 0.093 b 200.0 (86.5) 209.2 (64.2) 0.839 a
Stromal ND ND ND 25.0 (55) ND ND 96.7 (54.3) 75.7 (48.4) 0.495 a
a Values presented as mean (SD). P value was determined by Student’s t test. P values are corrected for ties.
b Values presented as median (interquartil range). P value was determined by Mann–Whitney U test. P values are corrected for ties.
ND = Not detectable
https://doi.org/10.1371/journal.pone.0200613.t004
AR-Vs in BPH and primary PCa
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AR-V7) expressions are upregulated by castration, while re-administration of androgens sup-
pressed their expression. In the present study, PCa showed high AR-V1 and AR-V7rv expres-
sion, while steroid (testosterone, 4-androstenedione, progesterone) expression was decreased
(unpublished data).
When the PCa group was stratified into Gleason7(3+4) and7(4+3), age was higher in
patients with Gleason7(4+3). This indicates that older patients tend to present more aggres-
sive PCa than younger patients. Despite the relatively small cohort number, a greater AR-V
expression was seen in PCa samples with a high-grade Gleason score compared to a low-grade
Gleason score. AR-V4 and AR-V7rv levels were higher in the high-grade ones. Even without
statistical significance, AR-V1 showed a higher distribution in high-grade tumors. In line with
these results, we found an inverse correlation between the AR-FL/AR-V4 ratio and the Glea-
son score, which indicate that AR-V expression increases with higher Gleason scores.
When we stratified PCa cases by whether biochemical relapse occurred or not, we observed
a similar expression of all mRNAs analyzed between those patients who had biochemical
recurrence and in those who did not present recurrence, which is in concordance with the
results reported by Zhao et al. [19]. They showed that neither the AR-V7 nor its negative
Fig 2. Histological score for immunohistochemical staining of AR-NTD, AR-CTD, and AR-V7. A variety of immunohistochemical staining
patterns for AR-NTD, AR-CTD and AR-V7 are shown. Epithelial nuclear staining (A) for AR-NTD (PG21) and AR-CTD (C19) are higher in
BPH samples than in PCa samples (P = 0.034 and P = 0.041, respectively). Although BPH group seems to have a higher AR-V7 H-Score, it was
not statistically different (P = 0.093). Epithelial cytoplasmatic staining (B) was not different between the groups. The bars represent the
minimum to maximum values.
https://doi.org/10.1371/journal.pone.0200613.g002
Fig 3. Representative images of IHC staining. 100X and 400X. For H-Score calculation we analyzed all over the slides.
https://doi.org/10.1371/journal.pone.0200613.g003
AR-Vs in BPH and primary PCa
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regulator AR-V1 were associated with biochemical recurrence in a cohort of men at indetermi-
nate risk of progression [19].
Some studies have reported a positive correlation between AR-V7 and AR-V1 in PCa sam-
ples [18, 19], in agreement with our data. Interestingly, Watson et al. [12] observed that
AR-V1 and AR-V7 co-expression results in complete avoidance of the gain of function con-
ferred by AR-V7, indicating that AR-V1 seems to play a negative role on AR-V7, which was
recently confirmed and well discussed by Zhan [14]. The higher expression of AR-V1 in carci-
noma samples compared with BPH samples seems to be very promising data, although it must
be confirmed with a larger number of patients. AR-V1 blocks the ability of AR-V7 to confer
castration-resistant cell growth, and when these isoforms are co-expressed, AR-V7 does not
transactivate its targets [14]. AR-V1 has an ability to selectively activate a canonical AR-FL sig-
nal. Thus, if both isoforms are expressed in both tissues, with PCa presenting higher levels of
Table 5. Correlation coefficients between AR-Vs and clinical features.
BPH
rs (P)
PCa
rs (P)
Correlation between AR-Vs
AR-V1 AR-V4 0.387 (0.035) 0.457 (0.022)
AR-V7rv 0.394 (0.031) -
Correlation between AR-Vs and clinical features
AR-V1 Estimated prostate weight 0.477 (0.025) -
AR-V4 Estimated prostate weight 0.711 (<0.001) -
Gleason - 0.493 (0.012)
Correlation between ratios and clinical features
AR-FL/AR-V1 Age at surgery -0.364 (0.048) -
AR-FL/AR-V4 Age at surgery -0.405 (0.027) -
Estimated prostate weight -0.495 (0.019) -
Gleason - -0.475 (0.016)
Spearman correlation for association between variables. The results are presented as rs (P). Values of P< 0.05 were
considered statistically significant. Only statistically significant correlations are showed.
https://doi.org/10.1371/journal.pone.0200613.t005
Table 6. Correlation coefficients between cell cycle-related and apoptosis-related genes and other variables.
BPH
rs (P)
PCa
rs (P)
Correlation between cell cycle-related and apoptosis-related genes and AR-Vs
BCL2 AR-FL - 0.464 (0.020)
AR-V7rv - 0.450 (0.024)
MDM2 AR-FL - 0.434 (0.030)
AR-V1 0.422 (0.028) 0.549 (0.004)
Correlation between apoptosis-related genes and ratio
BCL2 AR-FL/AR-V4 - 0.472 (0.017)
Correlation between cell cycle-related and apoptosis-related genes and clinical features
TP53 PSA - -0.439 (0.025)
BCL2/BAX Surgical specimen weight - -0.413 (0.036)
Spearman correlation for association between variables. The results are presented as rs (P). Only statistically
significant correlations are showed. Values of P< 0.05 were considered statistically significant.
https://doi.org/10.1371/journal.pone.0200613.t006
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AR-V1, it probably directs the canonical AR signal as the main pathway in primary and andro-
gen-responsive PCa. On the other hand, AR-V4, which is more highly expressed in BPH,
transactivates both canonical AR-targets and AR-V-specific targets. To our understanding,
this is an interesting finding of our work, since in this benign tissue, both AR-V7 and AR-FL
pathways could be activated, showing an absence of a trend to either route. As previously
described, advanced and aggressive PCa samples have a higher AR-V7 expression [9, 18],
which was confirmed by our work when samples were dichotomized based on their Gleason
scores. In this case, it is possible that AR-V7 levels surpass AR-V1 levels, favoring the “AR-
V7-pathway”, which was already reported in CRPC and metastasis [5, 8, 9, 11, 12, 18, 20, 23].
The presence, interaction and possible consequences of AR-Vs expression should be taken in
consideration also in benign tissue. In summary, BPH have more AR-V4 (which could activate
both AR-V7 and AR-FL pathways), primary PCa have more AR-V1 (to activate AR-FL canoni-
cal targets and inhibit AR-V7), and CRPC, according to the literature, have more AR-V7 (cas-
tration-resistant cell growth driver). Unfortunately, in this work we did not have access to
CRPC biopsy samples. In addition, the strong positive correlation between AR-V4 and Glea-
son score emphasized the role of AR-V4 in PCa progression, which is also indicated by the
positive correlation between prostate weight with AR-V1 and AR-V4 expression. In high-
grade PCa, AR-V4, which could activate both AR-V canonical-targets and AR-FL canonical-
targets, could enable the activation of both sides of the AR pathway, making it possible that the
cell takes advantage of both pathways.
The correlation between BCL2with AR-FL and AR-V7rv in PCa suggests an association
between the AR-mediated pathways and the antiapoptotic process involved in tumor develop-
ment. Elevation in the level of the BCL2 protein has been shown to provide protection from
apoptosis, and the BCL2 gene family is implicated in the development of CRPC and resistance
to therapy since its expression increases during progression of prostate cancers [24, 25]. These
findings corroborate the hypothesis that AR and AR-V7 have a role in the mechanisms of pro-
liferation and apoptosis, and may contribute to cancer progression. MDM2 was also positively
correlated with AR-FL in PCa, and with AR-V1 in PCa and BPH. However, the interactions
among AR, AR-Vs and MDM2 are poorly described. One study suggests that MDM2 induces
AR ubiquitination, promoting its degradation [26]. Therefore, the association between cell
cycle-related and apoptosis-related genes and AR-Vs suggests new ways to help understand
the development of primary PCa.
We used IHC to investigate protein expression in FFPE samples from BPH and primary
PCa. This technique is reliable and widely used in clinical diagnosis. Our approach to detect pro-
tein expression was based on three antibodies: AR-NTD (which recognizes AR-FL and AR-Vs),
AR-CTD (which recognizes AR-FL) and AR-V7 (specific to this isoform). Using two antibodies
against different regions of the AR protein (AR-NTD and AR-CTD), it is possible to successfully
show the overall frequency of C-terminal truncated AR-Vs [27]. We observed a wide distribution
of the AR-NTD/AR-CTD ratio in epithelial nuclei of PCa samples. This finding suggests the pres-
ence of AR-Vs transcripts that lack part or all of the C-terminus, which is in line with previous
work [27]. To detect AR-V7, we used a specific antibody against this isoform, rather than the
alternative approach to detect all truncated variants suggested by Zhang et al. [27].
Fig 4. Stratification of PCa samples between Gleason grade (7(3+4) and7(4+3). (A) Age at surgery. The group
low grade (7(3+4) was younger than the high grade group (7(4+3) (63 and 68 years, respectively. P = 0.047). (B)
AR-FL levels were similar between groups (P = 0.836). (C) AR-V1 levels failed to reach significance (P = 0.060), but
seems to be up-regulated in high grade group (7(4+3). (D) and (E) AR-V4 and AR-V7rv levels are higher in high
grade group (7(4+3) (P = 0.004 and P = 0.014). (F) AR-FL/AR-V4 ratio was higher in low grade group (7(3+4),
P = 0.021). The bars represent the minimum to maximum values.
https://doi.org/10.1371/journal.pone.0200613.g004
AR-Vs in BPH and primary PCa
PLOS ONE | https://doi.org/10.1371/journal.pone.0200613 July 20, 2018 13 / 17
We observed considerable heterogeneity in AR staining within samples. Epithelial cells
showed positive staining for the three antibodies in both groups. AR-NTD and AR-CTD had a
higher H-score (HS) in epithelial nuclei of BPH. AR-NTD was stained less intensively and
more heterogeneously in epithelial nuclei and stromal cells of PCa than in BPH, and this is
consistent with the report of Miyamoto [28]. AR-V7 showed the same trend, despite it failed
to reach statistical significance. It is important to note that this isoform was detected in epithe-
lial cells from BPH and PCa, and in stromal cytoplasm, but at lower levels. In addition, stromal
nuclei were positive only for AR-NTD, while stromal cytoplasm was positive for AR-V7. This
positive stromal staining is remarkable, due to the importance of stromal AR in the develop-
ment of normal prostate and BPH, and also in the growth and progression of PCa [29]. Of
note, positive staining observed with AR-NTD antibody may reflect the expression of other
variants than AR-FL and AR-V7 (like AR-V1, AR-V4).
AR-V7 protein expression was similar between the analyzed groups. Our results differ from
Guo [5], whose immunohistochemistry analysis on human prostate tissue revealed higher lev-
els of AR-V7 (AR3) in malignant prostate tissues compared with their benign counterparts.
An interesting finding of this author was a remarkable redistribution in AR-V7 cellular locali-
zation, showing high nuclear staining in hormone-resistant tumor samples compared with
their hormone-naïve counterparts, showing that the nuclear translocation of AR-V7 is signifi-
cantly increased in hormone-resistant tumors [5]. It is important to note that although our
results are different, we demonstrate both AR-FL and AR-V7 expression in epithelial and stro-
mal compartments. Although AR-V7 is truncated after exon 3 and lacks the complete nuclear
localization sequence, it has been identified in the nucleus of epithelial cells [5, 16, 20, 23].
For AR action, nuclear import is an essential step. Different AR-Vs have different abilities
to translocate to the nucleus. For example, AR-V7 is expressed predominantly in the nucleus
when alone, but other isoforms, like AR-V1 and AR-V4, mainly localize in the cytoplasm [14].
As is already known, nuclear import of AR requires the dimerization of the receptor, which is
also essential for AR-Vs. AR-V1, V4 and V6 heterodimerize with AR-V7, which facilitates
their nuclear localization. These AR-Vs can also heterodimerize with AR-FL (in presence or
absence of androgens), but their subcellular localization is not affected in androgen-deprived
conditions. When AR-FL is bound to an androgen, the isoforms are piggybacked into the
nucleus. This AR-V–AR-FL interaction can mitigate the ability of enzalutamide to inhibit
androgen-induced AR-FL nuclear localization [14]. AR-V7 is the most abundant AR-V in
clinical specimens, and its role in mediating castration resistance is sustained by clinical evi-
dence. The data presented by Zhan [14] indicates that besides its transcriptional activity,
AR-V7 could activate both AR-FL and other AR-Vs, which could be an important mechanism
of action. Although many AR-Vs localize mainly in the cytoplasm when expressed alone, their
clinical relevance should not be ignored. Since these AR-Vs are expressed together with
AR-V7, they could contribute to the development of resistance, possibly adding their functions
to the canonical transcriptional program of AR-FL. Nonetheless, this does not mean all AR-Vs
have a synergistic action; indeed, AR-V1 could block the capability of AR-V7 to induce castra-
tion-resistant proliferation [12, 14].
The use of AR-V7 expression has been proposed as a biomarker for PCa relapse [16, 20]
and even as a survival marker [20]. One of the proposed mechanisms of AR-V7 activity is that
it could activate AR-FL in the absence of hormones, explaining how cancer cells could use
AR-V7 as an escape from therapy [20]. Previous data has suggested that AR-V expression
increases as patients progress to malignant prostate adenocarcinoma, being a consequence of
therapy and a driver of therapy resistance [5]. In line with this theory, we believe that during
the evolution to hormone-independent, metastatic disease, prostate adenocarcinomas may
therefore express progressively more AR-Vs. Additionally, these results corroborate evidence
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shown in multiple studies from independent laboratories, which demonstrates that AR-V
expression correlates with the development of ADT resistance in numerous model systems
and clinical samples [5, 8, 11, 14, 17, 18].
However, it is noteworthy that AR-Vs are also expressed in benign tissue from BPH and in
primary PCa. All samples used in our research were obtained from patients who had never
undergone ADT, so our data do not support the suggestion of variants arising only after ther-
apy, as a response to the treatment. The current idea is that the presence of AR-Vs is also bio-
logically relevant in BPH and primary PCa. In addition, studies to help elucidate the role of
AR-Vs in benign tissue and hormone-naïve PCa are needed to better clarify the involvement
of these isoforms in the pathophysiology of prostatic tumors.
Conclusions
These results support the assumption that the constitutively active AR-Vs are involved in the
pathophysiology of prostatic tumors. Our data shows that the AR-Vs participate in different
proliferative events in prostate cells, yet the exact role of these isoforms in benign tissue and
primary cancer needs to be elucidated. The identification and functional characterization of
differentially expressed molecules between normal and tumoral tissues are fundamental steps
to achieving a better understanding not only of the carcinogenic process and the development
of new anti-tumoral strategies, but also a better understanding of the processes that govern
proliferation in benign tissues such as BPH. Additional studies aiming to elucidate in vitro
hormonal modulation of AR-Vs may contribute to the understanding of their role in prostate
physiology and tumor development and progress.
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